Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116271 · ClinicalTrials.gov registry record · Phase 2
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
A Phase 2 study of Colorectal Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 12
- Study locations
NCT01116271 is a Phase 2 study of Colorectal Cancer that has completed, run by AstraZeneca. The registered enrollment target is 32 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT01116271, a Phase 2 study of Colorectal Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG AZD6244
Study Locations (12)
North Carolina
- Reserach Site - Chapel Hill
- Research Site - Greenville
- Research Site - Washington
California
- Research Site - Los Angeles
- Research Site - Palm Springs
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Florida
- Research Site - Miami Beach
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01116271
The ClinicalTrials.gov registry entry for NCT01116271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan is the first listed.
NCT01116271 reports 12 study locations spanning 9 distinct geographic areas - top geographies include North Carolina, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01116271 about?
NCT01116271 is a clinical study titled "Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec". The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
What is the current status of trial NCT01116271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-04. Estimated completion is 2012-07.
What conditions does trial NCT01116271 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT01116271?
The interventions under investigation include: Irinotecan (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT01116271?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01116271 being conducted?
This trial has 12 study locations across California, Colorado, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.